Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation

Citation
P. Mehta et al., Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation, BONE MAR TR, 24(12), 1999, pp. 1323-1327
Citations number
11
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Journal title
BONE MARROW TRANSPLANTATION
ISSN journal
02683369 → ACNP
Volume
24
Issue
12
Year of publication
1999
Pages
1323 - 1327
Database
ISI
SICI code
0268-3369(199912)24:12<1323:ICOTIC>2.0.ZU;2-#
Abstract
The pharmacokinetics of tacrolimus have been studied in healthy volunteers and in adults undergoing bone marrow transplantation. However, there is lit tle information on the pharmacokinetics of tacrolimus in children undergoin g BMT, We studied pharmacokinetics of tacrolimus in seven patients (age 8-1 7 years) undergoing allogeneic stem cell transplantation. Four patients rec eived matched unrelated donor (MUD) transplants, two underwent HLA-matched related donor transplants, and one underwent an umbilical cord blood donor transplant. All patients received tacrolimus by continuous infusion at 0.03 -0.04 mg/kg/day beginning on the day prior to transplant. Tacrolimus whole blood concentrations were monitored by microparticle enzyme immunoassay. Ou r goal was to maintain a blood tacrolimus level of 10-20 mu g/ml, Once pati ents were tolerating oral medications, tacrolimus infusion was converted to oral dosing using a 4:1 conversion. Dose of tacrolimus and resulting tacro limus concentrations were recorded and the total body clearance of tacrolim us was calculated retrospectively. The mean clearance, based on first stead y-state tacrolimus concentrations necessary for achieving a therapeutic lev el (10-20 mu g/ml), was 108.1 ml/h/kg (range 79.7-142.0 ml/h/kg), greater t han that reported in adult BMT patients (71 +/- 34 ml/h/kg). The average do se required to achieve that therapeutic range was 0.0354 mg/kg/day as an in travenous continuous infusion. Over the entire course of intravenous tacrol imus, mean clearance was 97.0 ml/h/kg (range 33.4-153.3 ml/h/kg). In six of the seven patients, clearance values dropped after 2-4 weeks of therapy by an average of 32.5 ml/h/kg. In two patients, sharp drops in clearance were temporally related to changes in liver function tests. Three of the seven patients died of severe acute GVHD; all these had undergone matched unrelat ed donor transplantation, and two of these three had initial clearance leve ls over 120 ml/h/kg. Thus, children appear to have more rapid tacrolimus cl earance than adults and may need to begin therapy earlier in order to obtai n stable and optimal levels. More studies are needed to confirm these preli minary results.